Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AVXL | Stock Option (Right to Buy) | Award | $0 | +125K | +100% | $0.00 | 250K | Nov 19, 2024 | Common Stock | 125K | $10.09 | Direct | F1 |
Id | Content |
---|---|
F1 | On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 125,000 shares. |